Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 798 results for "Ibrutinib"

TG Therapeutics announces encouraging results from Phase II CL...

TG-1101 also appeared to abrogate ibrutinib related lymphocytosis with patients experiencing a median 75% reduction in their absolute lymphocyte count (ALC) by the end of month 3 following initiation of combination therapy and 70% of patients ... Individual.com, 22 hours ago

41 images for Ibrutinib

OncLive, 2 days ago
The ASCO Post, 1 week ago
OncLive, 2 weeks ago
Nasdaq, 2 weeks ago
OncLive, 1 month ago
NewsR.in, 1 month ago
Pharmaceutical Journal, 1 month ago
Pharmaceutical Journal, 1 month ago
Pharmaceutical Journal, 1 month ago
Pharmaceutical Journal, 1 month ago
Seeking Alpha

Janssen Research & Development Release: Ibrutinib (IMBRUVICA) HELIOS Interim Analysis Study Data Show Significant Reductions In Risk Of Progression Or Death In Patients With Previously-Treated Chronic Lymphocytic Leukemia

/PRNewswire/ --Data from the Phase 3 CLL3001 (HELIOS) trial demonstrated that the combination of ibrutinib (IMBRUVICA ® ) plus bendamustine and rituximab (BR) reduced the risk of progression or death by 80% and also significantly improved overall ...
 BioSpace1 month ago Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients  News-Medical.Net1 month ago Ibrutinib (IMBRUVICA A(r)) HELIOS Interim Analysis Study Data Show Significant Reductions in Risk of Progression or Death in Patients with Previously-Treated Chronic Lymphocytic Leukemia  Canada NewsWire1 month ago Ibrutinib (IMBRUVICA ®) HELIOS Interim Analysis Study Data Show Significant Reductions in Risk of Progression or Death in Patients with Previously-Treated Chronic Lymphocytic Leukemia  Canada NewsWire1 month ago
[x]  

European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA ibrutinib to Treat Waldenstrom's Macroglobulinemia

By a News Reporter-Staff News Editor at Pharma Business Week Pharmacyclics, Inc. (NASDAQ: PCYC) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending a ...
 Pharmacy Choice3 weeks ago Positive CHMP opinion recommends ibrutinib for the treatment of Waldenström's macroglobulinemia  Ecancer Medicalscience1 month ago JOHNSON & JOHNSON : Janssen Receives Positive CHMP Opinion Recommending IMBRUVICA® (ibrutinib) for the Treatment of Waldenström's Macroglobulinemia  4 Traders1 month ago Janssen Receives Positive CHMP Opinion Recommending IMBRUVICA® (ibrutinib) for the Treatment of Waldenström's Macroglobulinemia  Noodls1 month ago
[x]  

Ibrutinib shows promise in CLL/SLL

medwireNews: The addition of ibrutinib to bendamustine and rituximab significantly prolongs progression-free survival (PFS) in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL), according to the HELIOS trial. The ...
 MedWire News3 weeks ago

Ibrutinib (IMBRUVICA®▼) HELIOS-Daten aus einer Zwischenanalyse zeigen eine deutliche Reduzierung des Risikos der Progression oder des Todes bei Patienten mit zuvor behandelter chronischer lymphozytischer Leukämie

BEERSE, Belgien, June 1, 2015 /PRNewswire/ -- Die Originalsprache dieser Pressemitteilung ist Englisch. Übersetzungen ins Deutsche, Französische und Spanische werden von PR Newswire als besonderer Service für seine Kunden angeboten. NUR ...
 PR Newswire1 month ago

CLL: Ibrutinib Combo Significantly Extends Progression-free Survival in Treatment-Resistant Patients

CHICAGO—Adding ibrutinib to the standard bendamustine/rituximab (BR) regimen improves outcomes for patients with treatment-resistant chronic lymphocytic leukemia (CLL), according to the interim results of a randomized, double-blind, ...
 Oncology Times1 week ago Adding Ibrutinib to Bendamustine/Rituximab Offers Highly Favourable Results in Leukemia Treatment: Presented at EHA  FirstWord Pharma2 weeks ago Ibrutinib (IMBRUVICA®) Improved Survival for Treatment-Naive Chronic Lymphocytic Leukemia Patients in Phase III RESONATE-2 Trial  Noodls3 weeks ago Ibrutinib IMBRUVICA in Combination with Anti-PD-L1 Antibody MEDI4736 Study Commences for Patients with Two Relapsed/Refractory Blood Cancers  Pharmacy Choice3 weeks ago
[x]  

EMA recommends approval of Janssen's Imbruvica to treat Waldenstrom's macroglobulinaemia

The European Medicines Agency (EMA) has recommended extending the use of Imbruvica (ibrutinib) to include the treatment of patients with Waldenstrom's macroglobulinaemia, a rare blood cell cancer. Imbruvica is the first medicine that is recommended ...
 PharmaBiz1 month ago First medicine for rare blood cancer  Bionity.com1 month ago
Nasdaq

Updated Results From Phase 2 Clinical Trial of TG-1101 (Ublituximab) in Combination With Ibrutinib Confirms Robust Clinical Activity With a Favorable Safety Profile in Patients With Previously Treated

95% Overall Response Rate (ORR) in Patients with High-Risk CLL, the same patient population being studied in the Company's on-going Phase 3 GENUINE study being conducted under Special Protocol Assessment (SPA) 20% of High-Risk CLL patients achieved ...
 Fat Pitch Financials2 weeks ago TG Therapeutics : Updated Results From Phase 2 Clinical Trial of TG-1101 (Ublituximab) in Combination With Ibrutinib Confirms Robust Clinical Activity With a Favorable...  4 Traders2 weeks ago Chemotherapy-free triplet therapy appears safe, effective for B-cell malignancies  Orthopedics Today1 month ago TG Therapeutics Announces the Triple Combination of TG-1101, TGR-1202 and Ibrutinib is Safe and Highly Active in Patients With Advanced B-Cell Malignancies  Marketplace1 month ago
[x]  

2 Drugs Show Promise Against Blood Cancers

Ibrutinib, obinutuzumab slowed progression of common leukemia, non-Hodgkin lymphoma WebMD News from HealthDay By Dennis Thompson HealthDay Reporter SATURDAY, May 30, 2015 (HealthDay News) -- Two new drugs have shown promise in slowing the march ...
 WebMD1 month ago
[x]  

Rosetta Genomics Announces Selection of First Pilot Project Grant under Strategic Alliance with Moffitt Cancer Center

MCL is an aggressive B-cell lymphoma. Ibrutinib, a blockbuster pharmaceutical marketed by Pharmacyclics under the brand name of IMBRUVICA®, is a novel Bruton's tyrosine kinase (BTK) inhibitor that received U.S. Food and Drug Administration approval ...
 World Energy Source1 month ago Rosetta Genomics USA : Announces Selection of First Pilot Project Grant under Strategic Alliance with Moffitt Cancer Center  4 Traders1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Ibrutinib
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less